rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
9
|
pubmed:dateCreated |
2003-9-8
|
pubmed:abstractText |
The effects of a low-fat diet or a low-fat diet with the addition of a soy supplement were investigated in a pilot Phase II study for asymptomatic, hormonally naive prostate cancer patients with rising prostate-specific antigen (PSA) levels. Experimental Design: A two-step intervention was implemented. During step 1 patients were begun on a low-fat diet with a goal to reduce fat intake to 15% of total daily calories. On PSA progression, a soy protein supplement was added to the diet (step 2). The primary end point was PSA reduction by 50%. Secondary end points were PSA doubling time and time to progression (TTP). Serum was analyzed for changes in the sex hormone and insulin-like growth factor (IGF-I) axes.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
1078-0432
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
9
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
3282-7
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:12960113-Aged,
pubmed-meshheading:12960113-Carbohydrate Metabolism,
pubmed-meshheading:12960113-Diet,
pubmed-meshheading:12960113-Dietary Fats,
pubmed-meshheading:12960113-Humans,
pubmed-meshheading:12960113-Insulin-Like Growth Factor I,
pubmed-meshheading:12960113-Male,
pubmed-meshheading:12960113-Middle Aged,
pubmed-meshheading:12960113-Pilot Projects,
pubmed-meshheading:12960113-Prostate-Specific Antigen,
pubmed-meshheading:12960113-Prostatic Neoplasms,
pubmed-meshheading:12960113-Soybean Proteins,
pubmed-meshheading:12960113-Testosterone,
pubmed-meshheading:12960113-Thymine Nucleotides,
pubmed-meshheading:12960113-Treatment Outcome
|
pubmed:year |
2003
|
pubmed:articleTitle |
Minimal effect of a low-fat/high soy diet for asymptomatic, hormonally naive prostate cancer patients.
|
pubmed:affiliation |
Divisions of Hematology/Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|